Buchumschlag

Book of abstracts

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Haemophilia
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Book of Abstracts
Veröffentlicht: (2025)

Canadian clinical experience on switching from standard half‐life recombinant factor VIII (rFVIII), octocog alfa, to extended half‐life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada
von: Davide Matino, et al.
Veröffentlicht: (2024)

EAHAD statement on the ISTH clinical practice guideline for treatment of congenital haemophilia A and B
von: Pratima Chowdary, et al.
Veröffentlicht: (2024)

Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A
von: Jens Müller, et al.
Veröffentlicht: (2024)

Differences and similarities in patient‐reported outcomes among men and women with haemophilia
von: Christine L. Kempton, et al.
Veröffentlicht: (2024)

Women and girls’ participation in haemophilia clinical trials
von: Stacey A. Fedewa, et al.
Veröffentlicht: (2024)

Acquired bleeding disorders
von: Andreas Tiede, et al.
Veröffentlicht: (2024)

Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy
von: Robbin Itzler, et al.
Veröffentlicht: (2024)

Diagnosis and treatment of von Willebrand disease in 2024 and beyond
von: Paula James, et al.
Veröffentlicht: (2024)

Real‐world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi‐institutional case series
von: Kimberley Youkhana, et al.
Veröffentlicht: (2024)

Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience
von: Felipe Lemos, et al.
Veröffentlicht: (2024)

Defining success in haemophilia care – Are we doing it right?
von: Alok Srivastava
Veröffentlicht: (2024)

Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry
von: Konrad van der Zwet, et al.
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

AUTHOR INDEX
Veröffentlicht: (2024)

Race and ethnicity and the success of immune tolerance induction among people with severe haemophilia A in the United States
von: Stacey A. Fedewa, et al.
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Low‐dose emicizumab for more equitable access to prophylaxis in resource limited countries
von: Pier Mannuccio Mannucci, et al.
Veröffentlicht: (2024)

Knowledge gaps in health‐related quality of life research performed in children with bleeding disorders – A scoping review
von: Elise J. Huisman, et al.
Veröffentlicht: (2024)

Modulation of Haemostatic Balance in Combined von Willebrand Disease and Antithrombin Deficiency: A Comprehensive Family Study
von: Behnaz Pezeshkpoor, et al.
Veröffentlicht: (2024)

Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding
von: Cedric Hermans, et al.
Veröffentlicht: (2024)

Low vitamin C status and hypermobility‐related disorders in patients with bleeding disorder of unknown cause
von: Eva Leinøe, et al.
Veröffentlicht: (2024)

Sexual functioning in men with haemophilia: Data from the haemophilia in the Netherlands‐6 study
von: Tessa C. M. van Gastel, et al.
Veröffentlicht: (2024)

Research Letter: Patient Attitudes Towards Haemophilia Gene Therapy at a US Haemophilia Treatment Center
von: Callie Berkowitz, et al.
Veröffentlicht: (2024)

Origin of pathogenic variant and mosaicism in families with a sporadic case of haemophilia B
von: Annika Mårtensson, et al.
Veröffentlicht: (2024)

The importance and evolution of bleeding disorder registries
von: Huyen Tran, et al.
Veröffentlicht: (2024)

Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective
von: Wolfgang Miesbach, et al.
Veröffentlicht: (2024)

Development of the World Federation of Hemophilia Shared Decision‐Making Tool
von: Donna Coffin, et al.
Veröffentlicht: (2024)

Real world management of individuals with severe FXI deficiency and its impact on clinical outcomes: Experience from a haemophilia treatment centre
von: S Julia Wu, et al.
Veröffentlicht: (2024)

AUTHOR INDEX
Veröffentlicht: (2024)

Comparison of the kinematic analysis of indoor and outdoor gait in people with haemophilia and total knee replacement
von: Carlos Cruz‐Montecinos, et al.
Veröffentlicht: (2024)

Test–retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study
von: Randall Curtis, et al.
Veröffentlicht: (2024)

A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials
von: John Chapin, et al.
Veröffentlicht: (2024)

Efficacy and safety of recombinant activated factor VII in Glanzmann thrombasthenia: A systematic literature review
von: Paul Saultier, et al.
Veröffentlicht: (2024)

Quality of life of siblings of adolescents with severe haemophilia (FRATHEMO): An ancillary study to the TRANSHEMO project
von: Ngoc Anh Thu Nguyen, et al.
Veröffentlicht: (2024)

Acquired haemophilia A in Finland: A nationwide study of incidence, treatment and outcomes
von: Vuokko Nummi, et al.
Veröffentlicht: (2024)

The haemophilia joint health score for the assessment of joint health in patients with haemophilia
von: Cihan Ay, et al.
Veröffentlicht: (2024)

Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi‐criteria decision analysis
von: Daniel‐Aníbal García‐Diego, et al.
Veröffentlicht: (2024)

Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real‐world clinical experience
von: Robert Klamroth, et al.
Veröffentlicht: (2024)

The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti‐FVIII antibody
von: Tomoko Onishi, et al.
Veröffentlicht: (2024)